Interius BioTherapeutics raises $76M for GCT platform

By The Science Advisory Board staff writers

May 19, 2021 -- Interius BioTherapeutics has raised $76 million in fundraising to advance its gene and cell therapy (GCT) platform.

Initially, Interius will use the funding to treat hematologic malignancies by leveraging its platform to generate chimeric antigen receptor (CAR) T cells in vivo. This method bypasses the need for ex vivo manipulations and potentially toxic preconditioning chemotherapy required for standard CAR T-cell treatments. The company is focused on immuno-oncology indications that are not amenable to current gene therapy modalities.

The oversubscribed series A financing was co-led by Cormorant Asset Management and Fairmount Funds.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.